A 6-week randomised, double-blind, parallel-group trial evaluating compatibility and safety of FIAsp and insulin aspart with an external continuous subcutaneous insulin infusion system in adult subjects with type 1 diabetes
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Insulin aspart (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions; Registrational
- Acronyms onset 4
- Sponsors Novo Nordisk
- 29 Sep 2017 According to a Novo Nordisk media release, the US FDA has approved Fiasp for glycemic control in adults with tyep1 and type 2 diabetes based on data from this and other three trials ((231999, 226655, 232775 trials from ONSET programme).
- 10 Jan 2017 According to a Novo Nordisk media release, the European Commission has granted marketing authorization for Fiasp for the treatment of diabetes in adults based on data from this and other three trials (231999, 226655, 232775 trials from ONSET programme).
- 06 Jan 2017 According to a Novo Nordisk media release, Fiasp has received marketing authorization from Health Canada.